Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus

Anitua, Eduardo; Orive, Gorka; Sánchez-Ávila, RM; Heredia, P; Muruzábal, Francisco; Merayo‐Lloves, Jesús

doi:10.1080/14712598.2021.1945030

Cited by 24 publications

(9 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diverse protocols and procedures have been developed to obtain these type of blood derivatives. One of the common steps to obtain any of these blood-derived products is the withdrawal of a small volume of the patient own-blood, thus obtaining an autologous therapy [ 21 ]. However, in some cases, it is not possible to obtain an autologous product because some patients are not suitable to be donors due to certain health or physical conditions like systemic inflammatory diseases, age, and other types of disorders or comorbidities [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

“…Plasma rich in growth factors (PRGF) eye drops is a type of PRP with specific characteristics including moderate platelet concentration, platelet activation, and lack of leukocytes [ 15 , 20 ]. PRGF eye drops have been used for the treatment of several ocular surface diseases such as corneal epithelial defects, dry eye, neurotrophic keratitis and graft versus host diseases among others, obtaining encouraging clinical outcomes [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differential Protein Content between Fresh and Freeze-Dried Plasma Rich in Growth Factors Eye Drops

et al. 2022

Self Cite

View full text Add to dashboard Cite

The purpose of this study was to analyze the proteomic composition of plasma rich in growth factors eye drops (PRGF) in comparison to lyophilized PRGF eye drops (PRGF lyo). The differential protein expression of keratocyte (HK) cells after PRGF or PRGF lyo treatment was also determined. Blood from different donors was collected and processed to obtain PRGF and PRGF lyo eye drops. Then, HK cells were treated with both formulations. A proteomic analysis was performed to evaluate the differential proteomic profile between PRGF and PRGF lyo, and the differential protein expression by HK cells after treatment with both blood-derived products. About 280 proteins were detected between both blood-derived formulation, with only 8 of them reaching significant differences. Furthermore, 101 out of 3213 proteins showed statistically significant deregulation in HK cells after treatment with PRGF or PRGF lyo. Gene Ontology analysis showed that these significant deregulated proteins were involved in 30 functional processes. However, the Ingenuity Pathway Analysis showed that no significant differences were found in any of the identified processes. In summary, the present study show that no significant differences were found in the proteomic profile or in the signaling pathways activation in HK cells between PRGF and PRGF lyo.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Differential Protein Content between Fresh and Freeze-Dried Plasma Rich in Growth Factors Eye Drops

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In fertility procedures, where this technology is employed, the characteristics of the treated pathologies may support the use of leukocyte-poor or depleted plasma. Reducing the immunogenicity of the PRP product can potentially lower the risk of incompatibility or graft-versus-host disease (GVHD) between the embryo and implantation site, akin to observations in other tissues such as the ocular surface [25]. Moreover, decreasing the immunogenicity of the utilized PRP may reduce the likelihood of premature implantation failures, a factor associated with a higher recurrence of fertility problems [26].…”

Section: Leukocyte Content Of Platelet-rich Plasmasmentioning

confidence: 99%

Not all platelet-rich plasma are created equal

Cantero

2024

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of review This review aims to elucidate potential variations in clinical outcomes resulting from the use of different types of platelet-rich plasma (PRPs) in reproductive medicine. It seeks to explore the reasons behind the diverse results reported in various studies and assess the general features distinguishing different PRP formulations. Recent findings PRPs have found applications across diverse medical fields, generating controversy due to the variability in outcomes. The field of reproductive medicine, despite its limited published studies, is encountering a similar challenge as it integrates these treatments. Summary The multitude of PRP product brands in the market, coupled with ‘home-made’ PRPs, poses a significant barrier to establishing a common protocol for the preparation of standardized PRP products. This impediment hinders widespread adoption by clinicians, particularly in endometrial or ovarian treatments. Drawing from evidence in other medical disciplines, this review endeavors to compile essential characteristics that PRPs must possess, aiming to mitigate the impact of variables affecting results in forthcom ing studies.

show abstract

“…PRGF, a refined form of autologous plasma enriched in growth factors, has demonstrated significant efficacy in suppressing differentiation of myofibroblasts (which are involved in scar formation), in the regeneration of corneal tissue, and in healing the corneal epithelium. 1…”

Section: Allison J Chen MD Mphmentioning

confidence: 99%

Addressing corneal opacity after herpes zoster infection

Santhiago,

Sampaio,

Arroyo

et al. 2024

J Cataract Refract Surg

View full text Add to dashboard Cite

A 15-year-old boy was referred for corneal opacity evaluation. The patient had a previous herpes zoster virus (HZV) infection—varicella-zoster virus (VZV)—with ocular manifestation 1 year ago. After the infection, he developed a central corneal scar and decreased corrected distance visual acuity (CDVA) in the right eye. The slitlamp examination showed the right eye with central corneal opacity (involving anterior stroma), lacuna area between the haze, fluorescein negative, and no vascularization near the scar (Figure 1 JOURNAL/jcrs/04.03/02158034-202406000-00019/figure1/v/2024-05-21T162725Z/r/image-tiff ). The patient had been treated with oral valacyclovir and topical corticosteroids without any improvement of visual acuity or changes in opacity within the 1-year follow-up. His CDVA was 20/200 (−4.50 −0.75 × 25) in the right eye and counting fingers (−4.00) in the left eye. Intraocular pressure was 12 mm Hg in both eyes. Fundoscopy was normal in the right eye, but he had a macular scar in the left eye (diagnosed when he was 7 years). The left eye had no cornea signs. The patient has no comorbidity or previous surgeries. Considering this case, a corneal central scar in a 15-year-old boy, legally single eye only, and assuming it is an opacity in the anterior stroma, would you consider surgery for this patient? If so, which would you choose: Would you consider an excimer laser treatment of his ametropia while partially removing his opacity, a phototherapeutic keratectomy (PTK), or a PTK followed by a topography-guided treatment, femtosecond laser-assisted anterior lamellar keratoplasty (FALK), or deep anterior lamellar keratoplasty (DALK) or penetrating keratoplasty (depending on the scar depth)? Would you consider prophylactic acyclovir during and after surgery? Would you consider any other surgical step to prevent delayed corneal healing-persistent epithelial defect? Before the surgical approach, would you consider treating this patient with topical losartan (a transforming growth factor [TGF]-β signaling inhibitor)? Would you first perform the surgery (which one) and then start the medication? Furthermore, if so, how long would you treat this patient? Would you consider treatment with another medication?

show abstract

Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus

Cited by 24 publications

References 137 publications

Differential Protein Content between Fresh and Freeze-Dried Plasma Rich in Growth Factors Eye Drops

Differential Protein Content between Fresh and Freeze-Dried Plasma Rich in Growth Factors Eye Drops

Not all platelet-rich plasma are created equal

Addressing corneal opacity after herpes zoster infection

Contact Info

Product

Resources

About